SCHEMBL588360

SCHEMBL588360

CCCCCCCCc1ccc(CC2CCCC2(N)CO)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 10/20 0.43
SPHK2 Q9NRA0 5/20 0.43
ESR1 P03372 2/20 0.42
ADRA2A P08913 2/20 0.42
ADORA3 P0DMS8 2/20 0.42
TACR2 P21452 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
SHBG P04278 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
HSPD1 P10809 1/20 0.42
ADRB3 P13945 1/20 0.42
HTR2C P28335 1/20 0.42
HSPE1 P61604 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25532846 1.00 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL13880785 1.00 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL13880925 1.00 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL13880930 1.00 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL13880923 1.00 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL12645208 0.96 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL12645214 0.96 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL13880782 0.96 SPHK1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL12588101 0.95 TNNC1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3
SCHEMBL12645206 0.95 TNNC1 (0.43) SPHK1SPHK2ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010118298-A2 COMPOSITIONS AND METHODS FOR BIOACTIVE COATINGS TO IMPROVE ALLOGRAFT INCORPORATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2010-10-14 WO claimed
EP-3054870-B1 COMPRESSED BONE COMPOSITION AND METHODS OF USE THEREOF LIFENET HEALTH (US) 2023-08-16 EP disclosed
US-20230158205-A1 COMPRESSED BONE COMPOSITION AND METHODS OF USE THEREOF LIFENET HEALTH (US) 2023-05-25 US disclosed
US-11576999-B2 Compressed bone composition and methods of use thereof LIFENET HEALTH (US) 2023-02-14 US disclosed
US-20200368391-A1 COMPRESSED BONE COMPOSITION AND METHODS OF USE THEREOF TRUIST BANK 2020-11-26 US disclosed
US-10780196-B2 Compressed bone composition and methods of use thereof LIFENET HEALTH (US) 2020-09-22 US disclosed
US-10780196-B2 Compressed bone composition and methods of use thereof LIFENET HEALTH (US) 2020-09-22 US disclosed
US-10220116-B2 Liquefaction of bone matrix LIFENET HEALTH (US) 2019-03-05 US disclosed
US-9775931-B2 Liquefaction of bone matrix LIFENET HEALTH (US) 2017-10-03 US disclosed
US-20160317709-A1 LIQUEFACTION OF BONE MATRIX TRUIST BANK 2016-11-03 US disclosed
US-9345810-B2 Liquefaction of bone matrix LIFENET HEALTH (US) 2016-05-24 US disclosed
US-20150010607-A1 LIQUEFACTION OF BONE MATRIX TRUIST BANK 2015-01-08 US disclosed
WO-2013119873-A1 LIQUEFACTION OF BONE MATRIX LIFENET HEALTH (US) 2013-08-15 WO disclosed
WO-2012129073-A2 COMPOSITIONS AND METHODS FOR TISSUE ENGINEERING AND CELL BASED THERAPIES UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-09-27 WO disclosed
EP-2416767-A2 COMPOSITIONS AND METHODS FOR BIOACTIVE COATINGS TO IMPROVE ALLOGRAFT INCORPORATION University Of Virginia Patent Foundation (US) 2012-02-15 EP disclosed
US-7960588-B2 Benzyl cycloalkyl sphingosine 1-phosphate receptor modulators UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-06-14 US disclosed
WO-2010118298-A2 COMPOSITIONS AND METHODS FOR BIOACTIVE COATINGS TO IMPROVE ALLOGRAFT INCORPORATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2010-10-14 WO disclosed
WO-2010118298-A2 COMPOSITIONS AND METHODS FOR BIOACTIVE COATINGS TO IMPROVE ALLOGRAFT INCORPORATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2010-10-14 WO disclosed
US-20100249074-A1 BENZYL-CYCLOALKYL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2010-09-30 US disclosed
WO-2009043013-A2 BENZYL-CYCLOALKYL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10220116-B2 Liquefaction of bone matrix BMP2, BMP4, MATR3 SPHK1 2528/4885SPHK2 2541/4885ESR1 2481/4885
US-20150010607-A1 LIQUEFACTION OF BONE MATRIX BMP2, BMP4, MATR3 SPHK1 2528/4885SPHK2 2541/4885ESR1 2481/4885
US-20100249074-A1 BENZYL-CYCLOALKYL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS S1PR1, S1PR3, S1PR4 SPHK1 6/4885SPHK2 7/4885ESR1 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.